- Sarepta’s second-quarter revenue reported at $362.9 million, missing the estimate of $389.5 million.
- Net product revenues totaled $360.5 million, which exceeded the estimate of $354.6 million.
- Cash and cash equivalents were significantly lower than expected at $383.6 million, compared to an estimate of $536.4 million.
- The investment community’s sentiment is generally positive towards Sarepta with 17 buys, 3 holds, and 0 sells.
A look at Sarepta Therapeutics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sarepta Therapeutics, Inc. has a promising long-term outlook according to Smartkarma’s Smart Scores. The company scores high in growth, resilience, and momentum, indicating a positive trajectory for its future performance. With a focus on developing innovative RNA-based therapeutics for rare and infectious diseases, Sarepta is positioned to capture opportunities in the evolving healthcare industry.
While Sarepta’s value score is moderate and it does not offer dividends, its strong ratings in growth, resilience, and momentum are key indicators of its potential for long-term success. The company’s commitment to research and development, coupled with its global presence in providing medical solutions, sets a solid foundation for continued growth and innovation in the biopharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
